ERBB2 and breast carcinoma: NMIIA was increased upon inhibition of HER2 with neratinib relative to DMSO control treatment from HER3 immunoprecipitates (Fig 1A). Immunoprecipitation experiments were performed in BT474 and MDA-MB-453 breast cancer cells using a HER3, IgG control, or NMIIA antibody.